uniQure N.V. (QURE) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Stoke Therapeutics (STOK) has outperformed uniQure N.V. (QURE) over the past year, losing 11.1% versus a loss of 62.4%. Over five years, STOK leads with a +3.3% price change compared with -25.0% for QURE. uniQure N.V. is the larger company by market cap ($1.56 billion vs $1.55 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QURE | STOK |
|---|---|---|
| Share price | $22.54 | $23.95 |
| Market cap | $1.56B | $1.55B |
| 1-day change | -2.59% | -1.40% |
| YTD return | -5.81% | -23.47% |
| 1-year return | -62.41% | -11.06% |
| 5-year return | -25.02% | +3.27% |
| EPS (TTM) | $-4.03 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $71.50 | $40.22 |
| 52-week low | $8.73 | $20.32 |
| Distance from 52-week high | -68.48% | -40.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +176.53% | +93.99% |
| Average volume | 1.95M | 852.03K |
| Shares outstanding | 69.37M | 64.53M |
| Employees | 221 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STOK has outperformed QURE by 51.4 percentage points over the past year.
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
QURE vs STOK FAQ
Which is bigger, uniQure N.V. or Stoke Therapeutics?
uniQure N.V. (QURE) is larger, with a market capitalization of $1.56B compared with $1.55B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, QURE or STOK?
STOK returned -11.06% over the past 12 months, compared with -62.41% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are uniQure N.V. and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.